Analytical Data
-
Gene name
HLA-A*11:01&B2M&KRAS WT(VVVGAGGVGK) Monomer
- Application
-
Alternative Names
MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAV53343.1 (G25-T305)&P61769
-
Expression Region
AAV53343.1 (G25-T305)&P61769 (I21-M119)&VVVGAGGVGK
-
Molecular Weight
53-63 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the HLA-A*11:01/B2M/KRAS WT (VVVGAGGVGK) monomer recombinant protein is driven by the need to understand the immune response in various diseases, particularly cancer. HLA-A*11:01 is a major histocompatibility complex (MHC) class I allele that plays a crucial role in presenting peptides to CD8+ T cells, thereby influencing the immune system's ability to recognize and destroy tumor cells. The inclusion of beta-2-microglobulin (B2M) is essential for the stability and functionality of the HLA molecule, as it forms a heterodimer with the heavy chain of the MHC class I molecule. The KRAS gene, often mutated in cancers, provides a specific peptide (VVVGAGGVGK) that is relevant for neoantigen research, as it can elicit an immune response in patients with KRAS wild-type cancers. By generating and studying this specific recombinant protein complex, researchers aim to elucidate the interactions between tumor antigen presentation and T cell activation, which could lead to advancements in immunotherapies and personalized medicine. Understanding how the immune system responds to KRAS-derived peptides presented by HLA-A*11:01 could contribute to more effective cancer treatments, highlighting the importance of this research in the realm of oncology and immunology.
